Variety of qualified sufferers: CDEC reviewed the uncertainty in the volume of individuals with moderately severe to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some sufferers that are labeled as acquiring delicate or reasonable ailment might have a extreme bleeding